Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bbr7.5
Berberine – Forschung
Hilft wahrscheinlich
203 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Berberine scheint in 10 von 13 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1985–2026 mit einer typischen Studiengröße von 446 Teilnehmenden.
Basierend auf 203 Studien · 41 Meta-Analysen · 77 RCTs · 53,624 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
10geholfen2unklar1nicht geholfen· 190 weitere ohne bewertete Effektdaten
Cholesterol & lipidsVerbessert Lipidprofile und Blutzuckermarker · 8-12 Wochen
Hilft wahrscheinlich21 Studien
Digestive healthModuliert das Darmmikrobiom und unterstützt die gastrointestinale Funktion · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung18 Studien
Liver health
Gemischte Evidenz16 Studien
Women's healthUnterstützt einen gesunden Östrogenstoffwechsel und das hormonelle Gleichgewicht · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung15 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung14 Studien
Weight managementVerbesserter Fettstoffwechsel und Körperzusammensetzung · 4-12 Wochen
Hilft vermutlich11 Studien
Heart & blood pressureVerbessert Lipidprofile und Blutzuckermarker · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung10 Studien
InflammationSignifikante Verbesserungen des Blutzuckers und der Blutfette · 4-12 Wochen
Überwiegend Mechanismus / Beobachtung8 Studien
Cognitive function
Überwiegend Mechanismus / Beobachtung5 Studien
In Zahlen
Aus 65 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
78%
über Studien hinweg
Untersuchte Personen
54k
typische Studie: 446 Personen
Stärkste Designs
118
41 gepoolt, 77 randomisiert
Zeigte Nutzen
77%
10/13 Studien
Wie lange Studien liefen
1–4 Wochen
3
1–3 Monate
3
3+ Monate
1
Untersuchte Populationen
Type 2 diabetes patients4
NAFLD patients3
Cardiovascular disease patients2
Cancer patients2
Aktives Forschungsgebiet
140 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
198520052026
1HbA1c reductionMeta-Analysen=1,337 · large study2025
Einfach gesagt: However, further validation of these findings is necessary through extensive clinical studies with larger sample sizes.
Miao R et al. · Phytotherapy research : PTR (2025)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Borderline
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
For body mass index (BMI), curcumin was more effective than resveratrol (MD -1.27, 95%Cl -2.43 to -0.03) (P < 0.05).
Curcumin, resveratrol, silymarin, and berberine can effectively improve cardio-metabolic risk factors in T2DM, and different herbal phytochemicals have different clinical advantages.
3Total cholesterol reductionMeta-Analysen=4,838 · very large study2024
Einfach gesagt: Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
Hernandez AV et al. · Journal of dietary supplements (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Products with berberine alone had less robust effects on TC (MD -12.08 mg/dL [95%CI: -21.79 to -2.37]), LDL (MD -9.26 mg/dL [95%CI: -20.31 to 1.78]), and HDL (MD 1.38 mg/dL [95%CI: -1.27 to 4.03]) but TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23]).
Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
4Inflammatory biomarkers reductionMeta-Analysen=1,600 · large study2023
Einfach gesagt: However, more investigation and high-quality evidence must be conducted to obtain more comprehensive and generalizable results.
Vahedi-Mazdabadi Y et al. · Phytotherapy research : PTR (2023)
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
There are limitations to our findings, including low-quality studies and significant heterogeneity.
These interventions might be considered adjunct therapy to managing inflammation status.
5Glycemic control improvementMeta-Analysen=5,000 · very large study2024
Einfach gesagt: The finding of our umbrella showed that the supplementation of BBR could be effective in improving glycemic parameters and inflammatory marker in adults.
6Clinical efficacy rate improvementMeta-Analysen=952 · large study2024
Einfach gesagt: BBR demonstrates substantial efficacy in treating UC without causing severe adverse reactions and may serve as a viable complementary therapy.
Li J et al. · PloS one (2024)
Spürbar Schaden
← SchlechterKein EffektBesser →
Likely real
BBR considerably improved the clinical efficacy rate (RR = 1.22, 95% CI [1.15, 1.30], P < 0.00001), attenuated the Baron score (SMD = -1.72, 95% CI [-2.30, -1.13], P < 0.00001) and reduced the DAI score (SMD = -2.93, 95% CI [-4.42, -1.43], P < 0.00001).
Additionally, it ameliorated clinical symptoms (SMD = -2.74, 95% CI [-3.45, 2.02], P < 0.00001), diminished inflammatory responses (SMD = -1.59, 95% CI [-2.14, 1.04], P < 0.00001), and modulated immune reactions (SMD = 1.06,95% CI [0.24,1.87], P <0.00001).
Nonetheless, the impact of BBR on reducing adverse reactions was not statistically significant (RR = 0.75, 95% CI [0.42, 1.33], P > 0.05).
7Liver enzymes improvementMeta-Analysen=811 · large study2024
Einfach gesagt: This meta-analysis demonstrates berberine's efficacy in improving liver enzymes, lipid profile, and insulin sensitivity in NAFLD patients.
Nie Q et al. · Journal of translational medicine (2024)
This meta-analysis demonstrates berberine's efficacy in improving liver enzymes, lipid profile, and insulin sensitivity in NAFLD patients.
These results indicate that berberine shows promise as an adjunct therapy for NAFLD.
Einfach gesagt: Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Zhao H et al. · Reproductive health (2021)
Compared with metformin, treatment with myo-inositol + D-chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31-93.58]).
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Myo-inositol combined with D-chiro-inositol is particularly efficacious in menstrual recovery.
Einfach gesagt: Higher quality studies are needed to provide more high quality evidence.
Zhang LS et al. · The American journal of Chinese medicine (2019)
The results of meta-analysis showed that compared with the placebo group, berberine could significantly reduce the total cholesterol and low-density lipoprotein levels and elevate the high density lipoprotein level ( P<0.05 ).
Compared with the simvastatin group, berberine was effective only in reducing the level of triglyceride ( MD=-0.37 , 95% CI: - 0.66, - 0.07, P=0.02 ).
Compared with the simvastatin group, berberine plus simvastatin was more effective in reducing the level of triglyceride ( MD=-0.33 , 95% CI: - 0.46, - 0.20, P<0.00001 ) and total cholesterol ( MD=-0.36 , 95% CI: - 0.60, - 0.12, P=0.003 ).
Einfach gesagt: The dosage and treatment duration of Berberine and patients' age may modify the effect.
Liang Y et al. · Endocrine journal (2019)
We calculated weighted mean differences (WMD) and 95% confidence interval (CI) for fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated haemoglobin (HbA1c) levels.
The pool data showed that Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups.
Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years.
Einfach gesagt: This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect.
Lan J et al. · Journal of ethnopharmacology (2015)
This study indicates that berberine has comparable therapeutic effect on type 2 DM, hyperlipidemia and hypertension with no serious side effect.
Considering the relatively low cost compared with other first-line medicine and treatment, berberine might be a good alternative for low socioeconomic status patients to treat type 2 DM, hyperlipidemia, hypertension over long time period.
Due to overall limited quality of the included studies, the therapeutic benefit of berberine can be substantiated to a limited degree.